Alcon Inc. logo

Alcon Inc. (ALC)

Market Open
8 Dec, 15:14
NYSE NYSE
$
79. 56
-1.17
-1.46%
$
39.15B Market Cap
- P/E Ratio
1.06% Div Yield
11,746 Volume
- Eps
$ 80.73
Previous Close
Day Range
79.55 80.44
Year Range
71.55 99.2
Want to track ALC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 78 days
Alcon Analysts Increase Their Forecasts After Q2 Results

Alcon Analysts Increase Their Forecasts After Q2 Results

Alcon Inc. ALC reported mixed second-quarter results, after the closing bell on Tuesday.

Benzinga | 1 year ago
Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript

Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript

Alcon Inc. (NYSE:ALC ) Q2 2024 Earnings Conference Call August 21, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Graham Doyle - UBS Veronika Dubajova - Citi Ryan Zimmerman - BTIG David Adlington - JPMorgan Patrick Wood - Morgan Stanley Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Company Anthony Petrone - Mizuho Group Larry Biegelsen - Wells Fargo Michael Sarcone - Jefferies Issie Kirby - Redburn Atlantic Richard Felton - Goldman Sachs Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Company Brett Fishbin - KeyBanc Capital Markets Operator Greetings and welcome to the Alcon Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Zacks | 1 year ago
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Alcon's (ALC) Market Share Gains, New Launches Aid Growth

Alcon's (ALC) Market Share Gains, New Launches Aid Growth

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.

Zacks | 1 year ago
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics

Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics

Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks | 1 year ago
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?

Is Alcon (ALC) Outperforming Other Medical Stocks This Year?

Here is how Alcon (ALC) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

Zacks | 1 year ago
Here's Why Alcon (ALC) is a Strong Momentum Stock

Here's Why Alcon (ALC) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.

Zacks | 1 year ago
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H

Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H

We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.

Zacks | 1 year ago
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.

Zacks | 1 year ago
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.

Zacks | 1 year ago
Loading...
Load More